Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
20.20
-0.06 (-0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
August 10, 2022
Via
Benzinga
Recap: Arcturus Therapeutics Q2 Earnings
August 09, 2022
Arcturus Therapeutics (NASDAQ:ARCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
August 09, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Expert Ratings for Arcturus Therapeutics
May 10, 2022
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:
Via
Benzinga
Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study
April 20, 2022
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
August 01, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
What 6 Analyst Ratings Have To Say About Arcturus Therapeutics
July 19, 2022
Over the past 3 months, 6 analysts have published their opinion on Arcturus Therapeutics (NASDAQ:ARCT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 21, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
93 Biggest Movers From Yesterday
June 14, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...
Via
Benzinga
70 Stocks Moving In Monday's Mid-Day Session
June 13, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...
Via
Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
70 Biggest Movers From Friday
May 31, 2022
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
May 11, 2022
Upgrades
Via
Benzinga
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
May 09, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics's Earnings Outlook
May 06, 2022
Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
May 05, 2022
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months...
Via
Benzinga
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
May 05, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
April 27, 2022
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 22, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
28 Stocks Moving In Wednesday's Mid-Day Session
April 20, 2022
Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday. AlloVir, Inc. (NASDAQ: ALVR) shares climbed 39% to $7.52...
Via
Benzinga
Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points
April 20, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 250 points on Wednesday.
Via
Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
April 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 20, 2022
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 40.0% to $1.4 during Wednesday's pre-market session. The company's market cap stands at $39.8 million....
Via
Benzinga
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
April 20, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 25, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
March 22, 2022
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical...
Via
Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 18, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference
March 14, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.